21 U.S. Code § 1701 - Definitions
The term “drug” has the meaning given the term “controlled substance” in section 802(6) of this title.
The term “drug control” means any activity conducted by a National Drug Control Program agency involving supply reduction or demand reduction.
The term “Fund” means the fund established under section 1702(d) of this title.
The term “National Drug Control Program” means programs, policies, and activities undertaken by National Drug Control Program agencies pursuant to the responsibilities of such agencies under the National Drug Control Strategy, including any activities involving supply reduction, demand reduction, or State, local, and tribal affairs.
The term “National Drug Control Strategy” means the strategy developed and submitted to Congress under section 1705 of this title.
Unless the context clearly indicates otherwise, the term “Office” means the Office of National Drug Control Policy established under section 1702(a) of this title.
Except where otherwise provided, the term “appropriate congressional committees” means the Committee on the Judiciary, the Committee on Appropriations, and the Caucus on International Narcotics Control of the Senate and the Committee on Government Reform, the Committee on the Judiciary, and the Committee on Appropriations of the House of Representatives.
The term “law enforcement” or “drug law enforcement” means all efforts by a Federal, State, local, or tribal government agency to enforce the drug laws of the United States or any State, including investigation, arrest, prosecution, and incarceration or other punishments or penalties.
For repeal of section on Sept. 30, 2010, see section 1712 of this title.
This chapter, referred to in text, was in the original “this title”, meaning title VII of div. C of Pub. L. 105–277, Oct. 21, 1998, 112 Stat. 2681–670, which is classified principally to this chapter. For complete classification of title VII to the Code, see Short Title note set out below and Tables.
The repeal of this chapter and of the amendments made by this chapter, effective Sept. 30, 2003, by section 1712 of this title, as in effect on Sept. 30, 2003, has not been given effect in the Code, to reflect the probable intent of Congress, because of the amendment to section 1712 of this title by Pub. L. 109–469 which substituted “September 30, 2010” for “September 30, 2003” as the effective date of the repeal.
2006—(1)(G). Pub. L. 109–469, § 101(a)(2), substituted “, including the testing of employees;” for period at end.
Par. (1)(H) to (J). Pub. L. 109–469, § 101(a)(1), (3), added subpars. (H) to (J).
Par. (6). Pub. L. 109–469, § 101(b), inserted “, including any activities involving supply reduction, demand reduction, or State, local, and tribal affairs” before period at end.
Par. (7). Pub. L. 109–469, § 101(c), in introductory provisions, substituted “National Intelligence Program,” for “National Foreign Intelligence Program,” and inserted “or (for purposes of section 1703(d) of this title) an agency that is described in section 530C(a) of title 28,” after “Related Activities,”.
Par. (9). Pub. L. 109–469, § 101(d), substituted “indicates” for “implicates”.
Par. (10). Pub. L. 109–469, § 101(e), amended par. (10) generally. Prior to amendment, text defined the term “State and local affairs”.
Par. (11). Pub. L. 109–469, § 101(f), amended par. (11) generally. Prior to amendment, text defined the term “supply reduction”.
Pars. (12), (13). Pub. L. 109–469, § 101(g), added pars. (12) and (13).
Committee on Government Reform of House of Representatives changed to Committee on Oversight and Government Reform of House of Representatives by House Resolution No. 6, One Hundred Tenth Congress, Jan. 5, 2007.
By the authority vested in me as President by the Constitution and the laws of the United States of America, including the Office of National Drug Control [Policy] Reauthorization Act of 1998, (21 U.S.C. 1701
(b) The Task Force shall develop recommendations for the President on further executive and legislative actions that can be undertaken to address the problem of doping and drug use in sports. In developing the recommendations, the Task Force shall consider, among other things: (i) the health and safety of America’s athletes, in particular our Nation’s young people; (ii) the integrity of honest athletic competition; and (iii) the views and recommendations of State and local governments, the private sector, citizens, community groups, and nonprofit organizations, on actions to address this threat. The Task Force, through its Chairs, shall submit its recommendations to the President.
(c) The Director of the Office of National Drug Control Policy (the Director), the Secretary of the Department of Health and Human Services, and the Olympic Task Force Vice Chairs or their designees shall serve as the Task Force Chairs.
(d) To the extent permitted by law and at the request of the Chairs, agencies shall cooperate with and provide information to the Task Force.
(b) Pursuant to 21 U.S.C. 1701
(c) To assist the Director in carrying out these responsibilities as the United States Government representative to the WADA and to the extent permitted by law, Federal employees may serve in their official capacity,